Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer

Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer. Optimization of the available agents is desirable to improve tumor uptake and reduce side effects to non-target organs. This can be achieved, for instance, via linker modifications or multimerization approaches. In this study, we evaluated a small library of PSMA-targeting derivatives with modified linker residues, and selected the best candidate based on its binding affinity to PSMA. The lead compound was coupled to a chelator for radiolabeling, and subject to dimerization. The resulting molecules, 22 and 30, were highly PSMA specific (IC50 = 1.0-1.6 nM) and stable when radiolabeled with indium-111 (>90% stable in PBS and mouse serum up to 24 h). Moreover, [In-111]In-30 presented a high uptake in PSMA expressing LS174T cells, with 92.6% internalization compared to 34.1% for PSMA-617. Biodistribution studies in LS174T mice xenograft models showed that [In-111]In-30 had a higher tumor and kidney uptake compared to [In-111]In-PSMA-617, but increasing T/K and T/M ratios at 24 h p.i. Tumors could be clearly visualized at 1 h p.i. by SPECT/CT after administration of [In-111]In-22 and [In-111]In-PSMA-617, while [In-111]In-30 showed a clear signal at later time-points (e.g., 24 h p.i.).

Automated summary

This study evaluated PSMA-targeting derivatives with modified linker residues and selected the best candidate based on its affinity to PSMA. The lead compound was coupled to a chelator for radiolabeling and subject to dimerization. The resulting molecules, 22 and 30, showed high PSMA specificity and stability when radiolabeled with indium-111. Biodistribution studies in mice models demonstrated that [In-111]In-30 had higher tumor and kidney uptake compared to [In-111]In-PSMA-617, with improved T/K and T/M ratios at 24 h p.i.